{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wrobel ER"],"funding":["CDC","NIAID NIH HHS","CyanVac LLC","NIH","NIH HHS","CDC HHS"],"pagination":["37"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12865185"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["J paramyxovirus (JPV) is a non-segmented, negative-strand RNA virus in the Jeilongvirus genus of the Paramyxoviridae family. Recently, a recombinant JPV lacking the small hydrophobic protein (SH) gene (rJPV-∆SH) has been used as a viral vector for avian influenza virus H5N1 and HIV vaccine development. However, the rJPV-∆SH vector still causes morbidity and mortality in mice. To further develop this vaccine platform, we generated multiple recombinant JPV (rJPV) mutants and tested their pathogenicity in mice. We found that rJPV lacking the syncytial protein (SP) (rJPV-∆SP), rJPV with both SH and SP genes deleted (rJPV-ΔSHΔSP) and a JPV lacking coding sequences for SH, SP, and the putative X open reading frame (rJPV-∆3) were pathogenic in mice. Incorporating mutations in the L gene that medi"],"journal":["NPJ vaccines"],"pubmed_title":["Development of a J paramyxovirus-based vaccine vector."],"pmcid":["PMC12865185"],"funding_grant_id":["Emerging Infectious Disease Research Core Funds","R01AI128924","R01 AI128924"],"pubmed_authors":["Li Z","Piotrowski C","Welch SR","Gingerich MC","Gingerich A","Paton-Smith J","Spengler JR","He B","Karaaslan E","Wrobel ER"],"additional_accession":[]},"is_claimable":false,"name":"Development of a J paramyxovirus-based vaccine vector.","description":"J paramyxovirus (JPV) is a non-segmented, negative-strand RNA virus in the Jeilongvirus genus of the Paramyxoviridae family. Recently, a recombinant JPV lacking the small hydrophobic protein (SH) gene (rJPV-∆SH) has been used as a viral vector for avian influenza virus H5N1 and HIV vaccine development. However, the rJPV-∆SH vector still causes morbidity and mortality in mice. To further develop this vaccine platform, we generated multiple recombinant JPV (rJPV) mutants and tested their pathogenicity in mice. We found that rJPV lacking the syncytial protein (SP) (rJPV-∆SP), rJPV with both SH and SP genes deleted (rJPV-ΔSHΔSP) and a JPV lacking coding sequences for SH, SP, and the putative X open reading frame (rJPV-∆3) were pathogenic in mice. Incorporating mutations in the L gene that medi","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-07-15T13:29:14.616Z","creation":"2026-07-05T03:08:42.631Z"},"accession":"S-EPMC12865185","cross_references":{"pubmed":["41491822"],"doi":["10.1038/s41541-025-01359-8"]}}